These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35293206)

  • 1. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.
    Ferhati X; Jiménez-Moreno E; Hoyt EA; Salluce G; Cabeza-Cabrerizo M; Navo CD; Compañón I; Akkapeddi P; Matos MJ; Salaverri N; Garrido P; Martínez A; Laserna V; Murray TV; Jiménez-Osés G; Ravn P; Bernardes GJL; Corzana F
    J Am Chem Soc; 2022 Mar; 144(12):5284-5294. PubMed ID: 35293206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs.
    Zheng K; Chen Y; Wang J; Zheng L; Hutchinson M; Persson J; Ji J
    J Pharm Sci; 2019 Jan; 108(1):133-141. PubMed ID: 30458165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index.
    Wang Y; Xie F; Liu L; Xu X; Fan S; Zhong W; Zhou X
    Drug Deliv; 2022 Dec; 29(1):754-766. PubMed ID: 35244495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
    Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
    Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
    Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attachment Site Cysteine Thiol pK
    Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
    Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term stabilization of maleimide-thiol conjugates.
    Fontaine SD; Reid R; Robinson L; Ashley GW; Santi DV
    Bioconjug Chem; 2015 Jan; 26(1):145-52. PubMed ID: 25494821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
    Zhang L; Wang Z; Wang Z; Luo F; Guan M; Xu M; Li Y; Zhang Y; Wang Z; Wang W
    Bioconjug Chem; 2021 Jun; 32(6):1094-1104. PubMed ID: 34013721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Stability of Maleimide-Thiol Conjugation for Drug Targeting.
    Lahnsteiner M; Kastner A; Mayr J; Roller A; Keppler BK; Kowol CR
    Chemistry; 2020 Dec; 26(68):15867-15870. PubMed ID: 32871016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
    Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
    Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
    Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
    J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.
    Lyon RP; Setter JR; Bovee TD; Doronina SO; Hunter JH; Anderson ME; Balasubramanian CL; Duniho SM; Leiske CI; Li F; Senter PD
    Nat Biotechnol; 2014 Oct; 32(10):1059-62. PubMed ID: 25194818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
    Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
    Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.